Table 1 Demographic and clinical characteristics

From: Mapping striatal functional gradients and associated gene expression in Parkinson’s disease with continuous cognitive impairment

Variables

NC(n = 45)

MCI(n = 50)

PDD(n = 31)

HC(n = 40)

NCvsMCI

MCIvsPDD

NCvsPDD

MCIvsHC

NCvsHC

PDDvsHC

Age(years)

61.00 (9.50)

62.00 (13.00)

62.00 (6.00)

63.00 (5.75)

0.591

1.000

0.228

0.948

0.091

0.388

Gender(male/female)

20/25

28/22

17/14

18/22

0.261

0.919

0.373

0.300

0.959

0.411

Education(years)

12.00 (5.50)

9.50 (3.25)

9.00 (4.00)

12.00 (5.50)

1.000

0.601

0.324

0.069

0.191

0.004a

Duration(years)

5.00 (5.50)

3.00 (4.00)

5.00 (4.00)

0.104

0.132

0.472

HY

2.00 (0.75)

2.00 (0.63)

2.00 (1.50)

0.230

1.000

0.306

MDS-UPDRSIII

16.00 (17.50)

25.75 (21.5)

35.00 (11.00)

0.804

0.132

0.387

MMSE

29.00 (1.25)

29.00 (2.25)

24.00 (2.00)

−0.62 (0.46)

−1.78 (0.87)

−1.80 (0.50)

−3.01 (0.35)

−1.36 (0.47)

19.00 (5.00)

29.00 (2.00)

0.661

3.53e-11a

3.43e-14a

0.145

1.000

1.80e-15a

MoCa

27.00 (2.00)

15.00 (5.00)

27.00 (2.00)

3.49e-10a

4.24e-04a

1.63e-20a

1.45e-11a

1.000

7.78e-22a

Attention

−0.40 (0.22)

−1.43 (0.61)

−0.08 (0.89)

0.014a

5.18e-05a

1.46e-9a

8.98e-04a

0.949

9.69e-11a

Execution

−1.37 (0.20)

−2.86 (0.88)

−0.07 (0.34)

0.004a

1.55e-04a

7.84e-10a

3.94e-08a

0.030a

2.59e-16a

Language

−1.35 (0.25)

−2.34 (0.56)

−0.04 (0.90)

4.84e-04a

8.42e-05a

9.97e-12a

2.31e-07a

0.200

1.10e-15a

Memory

−2.41 (0.23)

−3.86 (0.54)

0.03 (1.06)

1.42e-04a

6.28e-05a

9.86e-13a

1.67e-08a

0.134

2.11e-17a

Visuospatial

−1.03 (0.35)

−2.08 (0.36)

0.06 (0.73)

0.031a

8.27e-05a

1.12e-08a

1.19e-07a

0.115

4.36e-16a

LEDD

337.50 (412.50)

300.00 (362.50)

450.00 (380.00)

1.000

0.839

1.000

  1. Continuous variables distributed non-normally are expressed as median(interquartile range-IQR), whilst categorical variable is presented with number of patients.
  2. HC healthy controls, NC normal cognitive, MCI mild cognitive impairment, PDD Parkinson’s disease dementia, MoCa Montreal Cognitive Assessment, HY Hoehn and Yahr stage, MDS-UPDRSIII the part III of the Movement Disorder Society-Sponsored Revision of the Unified Parkinson’s Disease Rating Scale, LEED levodopa equivalent dose, a indicates significant results of post hoc Dunn’s tests with Bonferroni correction.
  3. The bold value indicates significant results of post hoc Dunn’s tests with Bonferroni correction.